Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has
prompted the World Health Organization to declare a global eradication target by 2030 …

Abstract Background and Aim Various all‐oral direct‐acting antiviral (DAA) regimens are
being widely used in the treatment of human immunodeficiency virus (HIV)/hepatitis C virus …

Abstract Background & Aims Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)
coinfection is common in people who inject drugs (PWIDs). Recently,'high‐risk'behaviour …

Background & Aims Cure rates in response to retreatment with sofosbuvir/velpatasvir/
voxilaprevir (SOF/VEL/VOX) are high, but this regimen has not been studied in patients with …

The aim of this study was to evaluate the baseline demographics and real-life efficacy of
direct acting antivirals (DAAs) in HIV–HCV-positive patients as compared to patients with …

Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease
worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV …

Abstract Background and Aim Direct‐acting antivirals (DAAs) have increased hepatitis C
virus (HCV) treatment opportunities for vulnerable HIV/HCV coinfected persons. The aim of …

OBJECTIVES Data on the virologic response and tolerability of direct‐acting antivirals
(DAAs) are lacking in older people because these individuals are underrepresented in …

Abstract Background and Aim The efficacy of sofosbuvir (SOF)‐based regimens in the
treatment of chronic hepatitis C (HCV) patients with and without human immunodeficiency …

Background The aim of the present study was to evaluate in HIV-infected patients treated
with a direct-acting antiviral agent (DAA)-based regimen the variables associated with …